Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3480344 | 0.96 | TRPV4 (0.30) | TRPV4 | |
| SCHEMBL3483558 | 0.95 | TRPV4 (0.33) | TRPV4 | |
| Trifluoroacetic Acid SCHEMBL3480823 | 0.92 | — | — | |
| SCHEMBL3483962 | 0.91 | TRPV4 (0.33) | TRPV4 | |
| Trifluoroacetic Acid SCHEMBL3480222 | 0.88 | — | — | |
| SCHEMBL3483651 | 0.86 | TRPV4 (0.30) | TRPV4 | |
| Trifluoroacetic Acid SCHEMBL3483548 | 0.85 | CACNA1B (0.31) | CACNA1BTRPV4 | |
| Trifluoroacetic Acid SCHEMBL3480474 | 0.84 | CACNA1B (0.32) | CACNA1B | |
| Trifluoroacetic Acid SCHEMBL3942311 | 0.83 | TRPV4 (0.34) | CACNA1BTRPV4 | |
| SCHEMBL3483619 | 0.83 | TRPV4 (0.31) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049200-B1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC (CA) | 2015-04-29 | — | — | EP | disclosed |
| US-8440643-B2 | Inhibitors of beta-lactamase | METHYLGENE INC. (CA) | 2013-05-14 | — | — | US | disclosed |
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | 92229129 QUEBEC INC. (CA) | 2010-12-16 | — | — | US | disclosed |
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC. | 2010-11-04 | — | — | US | disclosed |
| EP-2024376-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | Merck & Co., Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007139729-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | MGAM, BPGM, PPME1 | CACNA1B 2462/4885TRPV4 4778/4885 |
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, MGAM2, PGLS | CACNA1B 405/4885TRPV4 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.